Literature DB >> 26057137

Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations.

Synnøve Eidem1, Sarah M Tete2, Åsne Jul-Larsen1, Katja Hoschler3, Emanuele Montomoli4, Karl A Brokstad5, Rebecca J Cox6.   

Abstract

Healthcare workers are at increased risk of influenza infection through direct patient care, particularly during the early stages of a pandemic. Although influenza vaccination is widely recommended in Healthcare workers, data on long-term immunogenicity of vaccination in healthcare workers are lacking. The present study was designed to assess the persistence of the humoral response after pandemic vaccination as well as the impact of repeated annual vaccination in healthcare workers (n=24). Pandemic influenza vaccination resulted in a significant increase in haemagglutination inhibition (HI) antibody titers with 93-100% of subjects achieving protective titers 21-days post each of the three annual vaccinations. Seroprotective antibodies measured by HI, microneutralization and single radial hemolysis assays were present in 77-94% of healthcare workers 6 months post-vaccination. Repeated vaccination resulted in an increased duration of seroprotective antibodies with seroprotective titers increasing from 35-62% 12 months after 2009 pandemic vaccination to 50-75% 12 months after 2010 vaccination. Furthermore, repeated annual vaccination augmented the avidity of influenza-specific IgG antibodies. In conclusion, we have shown that A(H1N1)pdm09 vaccination induces high seroprotective titers that persist for at least 6 months. We demonstrate that repeated vaccination is beneficial to healthcare workers and results in further avidity maturation of vaccine-induced antibodies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Avidity; Healthcare workers; Influenza; Long-term antibody persistence; Repeated vaccination

Mesh:

Substances:

Year:  2015        PMID: 26057137     DOI: 10.1016/j.vaccine.2015.05.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.

Authors:  Sonia Budroni; Francesca Buricchi; Andrea Cavallone; Patricia Bourguignon; Magalie Caubet; Vincent Dewar; Ugo D'Oro; Oretta Finco; Nathalie Garçon; Mohamed El Idrissi; Michel Janssens; Geert Leroux-Roels; Arnaud Marchant; Tino Schwarz; Pierre Van Damme; Gianfranco Volpini; Robbert van der Most; Arnaud M Didierlaurent; Wivine Burny
Journal:  NPJ Vaccines       Date:  2021-05-21       Impact factor: 7.344

2.  Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.

Authors:  Nuriban Valero-Pacheco; Marisol Pérez-Toledo; Miguel Ángel Villasís-Keever; Adriana Núñez-Valencia; Ilka Boscó-Gárate; Bernardo Lozano-Dubernard; Horacio Lara-Puente; Clara Espitia; Celia Alpuche-Aranda; Laura C Bonifaz; Lourdes Arriaga-Pizano; Rodolfo Pastelin-Palacios; Armando Isibasi; Constantino López-Macías
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

3.  Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years.

Authors:  Mai-Chi Trieu; Fan Zhou; Sarah Larteley Lartey; Saranya Sridhar; Siri Mjaaland; Rebecca Jane Cox
Journal:  NPJ Vaccines       Date:  2018-08-14       Impact factor: 7.344

4.  Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness.

Authors:  Gro Tunheim; Ida Laake; Anna Hayman Robertson; Kristian Waalen; Olav Hungnes; Lisbeth M Naess; Rebecca J Cox; Siri Mjaaland; Lill Trogstad
Journal:  Influenza Other Respir Viruses       Date:  2019-01-01       Impact factor: 4.380

5.  Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.

Authors:  Surender Khurana; Megan Hahn; Elizabeth M Coyle; Lisa R King; Tsai-Lien Lin; John Treanor; Andrea Sant; Hana Golding
Journal:  Nat Commun       Date:  2019-07-26       Impact factor: 14.919

6.  Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response.

Authors:  Anders Madsen; Åsne Jul-Larsen; Mai-Chi Trieu; Florian Krammer; Rebecca J Cox
Journal:  NPJ Vaccines       Date:  2021-04-01       Impact factor: 7.344

7.  Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).

Authors:  Maria Antonietta Isgrò; Giusy Trillò; Luigi Russo; Anna Lucia Tornesello; Luigi Buonaguro; Maria Lina Tornesello; Leonardo Miscio; Nicola Normanno; Attilio Antonio Montano Bianchi; Franco Maria Buonaguro; Ernesta Cavalcanti
Journal:  Infect Agent Cancer       Date:  2022-07-28       Impact factor: 3.698

8.  Model-based inference of neutralizing antibody avidities against influenza virus.

Authors:  Janina Linnik; Mohammedyaseen Syedbasha; Yvonne Hollenstein; Jörg Halter; Adrian Egli; Jörg Stelling
Journal:  PLoS Pathog       Date:  2022-01-31       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.